Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients
Recruitment status was Recruiting
The aim of the study is to develop a screenings tool that will enable hospital nurses to detect and stage cancer cachectic patients. The early detection and staging of cancer cachexia will assist the oncology team in providing the cachectic cancer patient tailor-made patient care.
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients|
- Nutritional Assessment [ Time Frame: 4 times in 6 months ] [ Designated as safety issue: No ]Patient-Generated Subjective Global Assessment Instrument is a measure for the nutritional status of the participants. The final score of this instruments devides participants into three categories: well-nourished, moderately nourished or suspected malnourished.
- Quality of Life [ Time Frame: 4 times in 6 months ] [ Designated as safety issue: No ]The EORTC-QlQ questionnaire will be used to assess the quality of life of the participants.
- Anthropometric measurements [ Time Frame: 4 times in 6 months ] [ Designated as safety issue: No ]
Mid-upper arm circumference will be measured to have an idea of the muscle mass.
Hand Grip Strength will be measured to obtain an idea of the muscle strength. Weight will be measured during every occasion. Question will be asked about weight loss during the last 6 months. Body composition will be measured by Bio-impedance assessment to obtain an indication of the fat-free mass.
Changes of all these measurements will be monitored.
- Markers of inflammation/metabolic disturbance [ Time Frame: 4 times in 6 months ] [ Designated as safety issue: No ]Biomarkers will be selected as part of the routine hospital assessment. These markers are C-reactief proteïne, albumin, creatinin, hemoglobin and Lactate dehydrogenase (LDH). These markers are a measure of the nutritional status and are seen as markers for the catabolic state of cachectic cancer patients.
Biospecimen Retention: Samples Without DNA
The blood sample that will be collected is part of the routine hospital assessment. The biomarkers that will be measured are albumine, creatine, CRP, hemoglobin and Lactate dehydrogenase (LDH).
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||June 2013|
|Estimated Primary Completion Date:||September 2012 (Final data collection date for primary outcome measure)|
As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.
In this cross-sectional study, the participants will complete 4 times a set of questionnaires and measurements. The data that will be collected is:
age; sex; height; weight; type of tumour; classification of malignant tumours (TNM); progression of tumour and used therapy; blood sample to analyse albumin, creatine, hemoglobin, LDH and CRP; use of parental nutrition; dietary assessment; use of nutritional supplements; Quality of Life by using the EORTC-QlQ; Subjective Global Assessment; presence of Percutaneous endoscopic gastrostomy; use of enteral or parenteral nutrition; body composition based on a Bio Impedance Assessment; hand grip strength and mid upper arm circumference. Based on all these data points a easy to use tool/score for a hospital setting will be created. During the first assessment the measurements will be done in the morning and the evening to test the reproducibility.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01533909
|Contact: Christophe Matthys, PhDemail@example.com|
|Contact: Ann Meulemans, PhD||+3216 firstname.lastname@example.org|
|University Hospital Leuven||Recruiting|
|Leuven, Vlaams Brabant, Belgium, 3000|
|Principal Investigator:||Ignace Vergote, PhD||Universitaire Ziekenhuizen Leuven|